


Reuters Company Research

Samaritan Pharmaceuticals, Inc. (LIV)

20 Jan 2006

Performance Rating: **Outperform**



Share Price Summary

Close Price on 1/20/06.....	\$0.40
Absolute Price Change on 1/20/06.....	0.01
Percent Change.....	2.56%
Off 52-Week High.....	-58.76%
Over 52-Week Low.....	25.00%
Beta.....	0.777

Overview

Float (mil).....	127.700
10 Day Average Volume (mil).....	0.079
1 Day Volume Change on 1/20/06.....	-6.82%
Market Capitalization (mil).....	\$.54
TTM Price/Earnings.....	NA
Price/Earnings Current Fiscal Year Estimate.....	NM

Percent Price Change

	LIV	S&P 500
Year to Date.....	0.00	1.06
One Year.....	-56.99	8.02
Two Years.....	-13.04	10.51
Three Years.....	175.86	42.17
Five Years.....	-52.59	-7.27
Ten Years.....	NA	NA

Table of Contents

Reuters Rating	2	Significant Developments continued	4	Stock Price Rationale	7
Getting Acquainted	3	Share Price Trends	5	Expectations and Credibility	8
Significant Developments	4	General Sentiment	6	Footprints of Success	9

REUTERS COMPANY REPORT DISCLAIMER

This research report is provided for informational purposes only and on the condition that it will not form the sole basis for any investment decision. Reference to any company is not a recommendation to buy or sell the shares of such company. The information used for, or presented in, this report has been obtained from sources believed to be reliable, but Reuters makes no representation as to the accuracy or completeness of such information. This report is intended only for users in the United States. Reuters has no obligation to update, modify or amend this report or to otherwise notify a reader thereof in the event that any matter stated herein becomes inaccurate. Reuters and/or its affiliates/investors may hold securities positions in the companies discussed in this report and may frequently trade in such positions. Such investments may be inconsistent with the quantitative analysis provided in this report.

This report was generated using a proprietary quantitative model that leverages widely accepted statistical methods and financial concepts to rank and rate a universe of more than 4700 US companies and US-listed ADRs with a market capitalization greater than \$50mm based on a series of financial attributes. These ratings are not intended as an indication of how an individual's investment will perform. As used in this report, "Outperform" designates the companies that rank in the top 30% of companies covered by Reuters, "Neutral" designates the middle 40%, and the bottom 30% are designated "Underperform". All ratings are relative to the universe of companies covered by Reuters and not to any specific benchmark.

Performance Rating: Outperform

Reuters ratings are based on a proprietary model that leverages widely accepted statistical methods and financial concepts to select attributes shown to be strong indicators of future stock price performance and applies these to rank stocks along a normal distribution curve. Ranks for Fundamental Quality, Value Catch-up, Operational Trends and Technical Factors are combined into a Composite Rating of Outperform, Neutral or Underperform.


Reuters Composite Rating

We cannot guarantee that each stock will perform in accordance with its rank. But we do believe that over the long term, stocks rated Outperform (30% of all stocks we rate) will, in the aggregate, outperform stocks rated Neutral (40% of all stocks we rate), and that stocks rated Neutral will, in the aggregate, outperform stocks rated Underperform (30%). All analysis is based on publicly available company financials, fundamental ratios, relative rankings of financial data and ratios, and observed security prices.



LIV shares are presently rated **OUTPERFORM**. No forecast is made for the stock market as a whole. However, we do believe that whichever way the market moves, stocks rated **OUTPERFORM** have, in the aggregate, a higher probability of performing better than most others.


Component Rating



"Under" = Underperform

Component Weight

Types of investment criteria differ in how useful they are for predicting future stock movement. Based on our research, the Composite Rank assumes these relative degrees of importance.



Fundamental Quality Component: Underperform

This rating is based on characteristics traditionally associated with "good" companies. We focus on how each company measures up against others, and give careful attention to recent improvement or slippage relative to other companies. TTM = Trailing Twelve Months.

	Very Negative	Negative	Neutral	Positive	Very Positive
TTM Return on Investment	█				
Improvement in TTM Return on Investment	█				
TTM Pretax Margin			█		
Improvement in TTM Pretax Margin			█		
Depreciation in Excess of Capital Spending Needs	█				
Issuance/Repurchase of Common Shares	█				
Common Shares Dilution			█		
Presence/Absence of Unusual Income Items			█		

Value Catch-up Component: Outperform

This rating measures the extent to which the share price adequately reflects improving or eroding fundamentals, and favors shares whose prices have been slower to "catch up" to improving performance measures. TTM = Trailing Twelve Months.

	Very Negative	Negative	Neutral	Positive	Very Positive
Price Catch-up with TTM Earnings					█
Price Catch-up to TTM Sales					█
Price Catch-up to TTM Free Cash Flow					█
Price Catch-up to MRQ Book Value					█

Operational Trends Component: Neutral

This rating reflects how strong a company's recent Sales and EPS (reported as per GAAP) growth have been relative to other companies we rate. MRQ = Most Recent Quarter. TTM = Trailing Twelve Months.

	Very Negative	Negative	Neutral	Positive	Very Positive
Most Recent Quarter EPS Growth	█				
Improvement in EPS Growth for Consecutive Quarters	█				
Improvement in EPS Growth (MRQ vs. TTM)		█			
Most Recent Quarter Sales Growth			█		
Improvement in Sales Growth (MRQ vs. TTM)			█		█

Peer Comparison

This section shows the comparison of key components between LIV and several of its peers.


Company Name (Ticker)	Composite Rating	Fundamental Quality	Technical Factors	Value Catch-up	Operational Trends
Samaritan Pharm... (LIV)	Outperform	Underperform	Underperform	Outperform	Neutral

Technical Factors: Underperform


This rating is based on analyses of share price movements over a variety of time periods. We compare performance characteristics of individual stocks with those of all the others we rate. Generally speaking, our goal is to favor up-trending shares that have experienced recent corrections and de-emphasize down-trending shares experiencing uncharacteristic periods of strength. Here is how LIV shares performed during the various periods we examined.

Price Change	
Past 7 days	0.0%
Past 30 days	-14.9%
Past 60 days	-9.1%


Change for Past 180 Days: -16.7%




Change Between 60 and 30 Days Ago: 6.8%



Change Between 180 and 60 Days Ago: -8.3%



Change Between 180 and 90 Days Ago: 2.1%



Getting Acquainted

Start your analysis by learning what the company does, how well it does it, where it stands relative to peers, and whether aspects of the corporate structure or capitalization are bothersome to you.

Business Summary

Samaritan Pharmaceuticals Inc. (Samaritan) is a biopharmaceutical company, focused on the development of therapeutic and diagnostic products for patients suffering from acquired immune deficiency syndrome (AIDS), Alzheimer's, cancer and cardiovascular disease. Samaritan is engaged in two distinct drug development programs, the AIDS/human immunodeficiency virus (HIV) program and the Alzheimer's program. The majority of the Company's resources have been expended in the pursuit of the United States Food and Drug Administration (FDA) required preclinical studies, and Phase II/III clinical trials, for its HIV drug SP-01A, an oral entry inhibitor. Samaritan has also devoted major resources to its Alzheimer's technology, which features three promising therapeutics: SP-04, SP-08 and SP-233 two stem cell, neuron differentiation therapies; SP-sc4 and SP-sc7 predictive Alzheimer's diagnostic, and an Alzheimer's animal model.

Contact Info

Samaritan Pharmaceuticals, Inc. is headquartered at:
101 Convention Center Drive, Suite 310, Las Vegas, NV, 89109
United States
(702) 735-7001
www.samaritanpharma.com
Eugene Boyle, CFO/COO

Financial Trends

TTM = Trailing Twelve Months, * = Most Recent Quarter.

Fiscal Year Ending	12/31/00	12/31/01	12/31/02	12/31/03	12/31/04	TTM	Historic Growth Rates		
							3 Year	5 Year	10 Year
Sales (mil)	\$0.0	\$0.0	\$0.0	\$0.3	\$0.0	\$0.1	NA	NA	NA
EPS (GAAP)	(\$0.21)	(\$0.17)	(\$0.08)	(\$0.07)	(\$0.04)	(\$0.05)	NA	NA	NA
Dividends/Share	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	NA	NA	NA
Book Value/Share	(\$0.03)	\$0.00	(\$0.01)	\$0.00	\$0.04	* \$0.02	NA	NA	NA
Tangible Book Value/Sh.	(\$0.04)	\$0.00	(\$0.02)	\$0.00	\$0.03	* \$0.02	NA	NA	NA
Cash Flow/Share	(\$0.21)	(\$0.17)	(\$0.08)	(\$0.07)	(\$0.04)	(\$0.05)	NA	NA	NA
Free Cash Flow/Share	(\$0.07)	(\$0.06)	(\$0.04)	(\$0.03)	(\$0.03)	(\$0.04)	NA	NA	NA

Key Ratios

Fiscal Year Ending	12/31/00	12/31/01	12/31/02	12/31/03	12/31/04	TTM	Historic Averages		
							3 Year	5 Year	10 Year
% Sales Growth	NA	NA	NA	NM	(100.0)	(46.0)	NA	NA	NA
% EPS Growth	-NM	(22.2)	(52.1)	(13.3)	(43.5)	24.9	(36.3)	NA	NA
% Gross Margin	NA	NA	NA	100.0	NA	NA	NA	NA	NA
% Operating Margin	-NM	-NM	-NM	(2,208.0)	-NM	(4,541.5)	NA	NA	NA
% Tax Rate	0.0	0.0	0.0	0.0	0.0	NA	0.0	0.0	NA
% Return on Assets	(601.6)	(638.3)	(612.7)	(825.1)	(164.2)	(127.0)	(534.0)	(568.4)	NA
% Return on Investment	369.3	391.8	592.1	6,857.1	(181.7)	(137.7)	2,422.5	1,605.7	NA
% Return on Equity	297.8	316.0	433.8	1,670.2	(181.7)	(137.7)	640.8	507.2	NA
Asset Turnover	0.0	0.0	0.0	0.4	0.0	0.0	0.1	0.1	NA
Receivables Turnover	NA	NA	NA	NM	0.0	NA	NA	NA	NA
Inventory Turnover	NA	NA	NA	NA	NA	NA	NA	NA	NA

Equity Information

Whether you are willing to accept companies that have or don't have major shareholders with controlling ownership blocks, multiple classes of common, or convertible debt or preferred issues is a matter of individual preference. Look here for anything along these lines that might make you more or less inclined to invest in this company.

Common Stock \$.001 Par, 11/05, 200M auth., 136,028,761 o/s, net of shares in Treas. @ cost. Insiders own 21% (includes 20.2M options). IPO: N/A. 8/04, Exchange changed from OTC to AMEX.

Analyst Footnotes

Look for accounting changes, restructurings, etc. which may affect how useful historic data is in assessing future company prospects.

FY'02 Q's are reclassified. 6/02 Summarized Q & Q = 6 months. 12/01 annual I/S is restated.

Peer Comparison


This table gives an indication of how Samaritan Pharmaceuticals, Inc. stands in key respects compared with companies in the Biotechnology & Drugs Industry

Company Name (Ticker)	Last Fiscal Year	Current Fiscal	Projected Price/Sales	Operating EPS	Current Fiscal	P/E Based on	EPS % Growth	EPS % Growth
	Revenue (mil)	Year Projected Revenue (mil)			Year Projected	Current Year		
Samaritan Pharm... (LIV)	\$0.0	\$0.2	NM	(\$0.04)	(\$0.04)	NM	NA	NA

Significant Developments

This page lists significant news developments related to Samaritan Pharmaceuticals, Inc. and shows how key stories may have an impact on the stock price. When looking at the chart, note the extent to which share price reactions to stories was temporary or lasting.

Significant News Stories Mapped to Price Chart



Significant News Stories

A. January 3, 2006. Samaritan Pharmaceuticals, Inc. Kicks Off Second HIV Phase II Monotherapy Trial Samaritan Pharmaceuticals, Inc. announced that it is conducting a second Phase IIb monotherapy trial to further study the effects of SP-01A for 28 days. This 28-day monotherapy study will allow the Company to gain longer-term data on SP-01A as an oral entry inhibitor and possible candidate to treat HIV drug resistance patients.

B. December 14, 2005. Samaritan Pharmaceuticals, Inc. In-Licenses Greece & Cyprus Marketing Rights For Amphocil From Three Rivers Pharmaceuticals Samaritan Pharmaceuticals, Inc. announced that its European subsidiary, Samaritan Europe has entered into an exclusive distribution agreement with Three Rivers Pharmaceuticals for the marketing and sales of Amphocil (amphotericin B cholesteryl sulfate complex for injection) in Greece and Cyprus.

C. August 1, 2005. Samaritan Pharmaceuticals, Inc. Plans to Expand Its Business to Europe Samaritan Pharmaceuticals, Inc. announced that its plans to expand its business to Athens, Greece, (Samaritan Europe), creating a European presence.

D. June 2, 2005. Samaritan Pharmaceuticals, Inc. Contracts with Sebiopharm of Paris, France for Preclinical Pharmacology Study Samaritan Pharmaceuticals, Inc. announced that it has contracted with Sebiopharm, Paris, France to perform preclinical pharmacokinetic studies with the Company's lead compounds. Pharmacokinetic studies are designed to yield information as to the extent and duration of systemic exposure of a drug on the human body.

Share Price Trends


Stock price trends depict the collective opinion of the investment community. You don't have to agree with consensus views but seeing how others feel can help you decide what to look for as you go further in your analysis. Consider it similar to reading a review before seeing a movie.

1 Year Price Chart with Bollinger Bands and Relative Strength


Technical analysts believe a narrowing of the bands suggests a significant price movement, up or down, will soon occur. Also, many say stocks that move outside the bands and then back inside will soon move toward the opposite band. The Relative Strength Index (RSI) calculates the strength of the current price movement compared to other recent moves and may signal when a trend is unsustainable. Technical analysts also believe RSI peaks/valleys forecast changes in share price trends.




10 Year Price Chart (Monthly)




5 Year Price Chart (Monthly)



6 Month Price Chart (Daily)



1 Month Price Chart (Daily)



General Sentiment

You can follow popular opinion or choose a contrarian's strategy. Either way, you should know whether the Street is bullish or bearish. Investor sentiment is typically positive when the 50-day moving average is rising, especially if it's also above the 200-day moving average. Additionally, changes in price trend can be deemed more definitive if supported by higher than normal volume.

52 Week Price History



Price History

Calendar Year	1997	1998	1999	2000	2001	2002	2003	2004	2005
High Price	NA	NA	NA	5.25	0.94	0.33	0.90	1.69	1.14
Low Price	NA	NA	NA	0.38	0.11	0.13	0.13	0.33	0.32
Year End Price	NA	NA	NA	0.47	0.13	0.16	0.37	0.98	0.40
High P/E	NA	NA	NA	NA	NA	NA	NA	NA	NA
Low P/E	NA	NA	NA	NA	NA	NA	NA	NA	NA
Year End P/E	NA	NA	NA	NM	NM	NM	NM	NM	NA
Dividend Yield	NA	NA	NA	NM	NM	NM	NM	NM	NA

Price Performance

When stocks significantly beat or trail the S&P 500 or the industry, investors are looking more intently at company-specific matters than general-market factors. In the two percentile rank columns, a high "Rank in Industry" coupled with a low "Industry Rank" could signify a hot stock in a cold industry. The reverse, is also noteworthy.

Time Period	Actual Change	Percent Change	vs. S&P 500	vs. Industry	Rank in Industry	Industry Rank
4 Week	(0.07)	(14.9)%	(14.4)%	(14.7)%	7	40
13 Week	(0.05)	(11.1)%	(16.9)%	(19.9)%	23	58
26 Week	(0.02)	(4.8)%	(6.9)%	(14.6)%	45	70
52 Week	(0.53)	(57.0)%	(60.2)%	(69.0)%	14	89
Year To Date	0.00	0.0%	(1.0)%	(1.3)%	33	49

BarChartKey
YTD 4 Wk.



Rank Key
Worst Best 1 100

Insider Trading

Insider buying can be seen as bullish because, presumably, their company knowledge is superior. However, insider sales are less reliable because insiders may sell for a variety of reasons that have nothing to do with their opinion of the stock.

In the last 6 months, there have been no insider purchases, and there have been no insider sales.

Net Change (6 months) 0 mil
6 Month Net Transactions 0

Institutional Ownership

It's worthwhile to know what institutions are doing simply because their stock positions can be so large. In the short term, stocks will perform well if institutions are buying and perform poorly if institutions are selling.

8 institutions own 0.6% of the 0.14 billion common shares outstanding. This is lower than the average institutional ownership of the Biotechnology & Drugs Industry at 43.7%, and lower than the average of the S&P 500 as a whole which is 64.9%.

Net Change (3 month) 0.0%
Net Purchases (3 month) 0.02 mil
Shares Purchased (3 month) 0.03 mil
Shares Sold (3 month) 0.00 mil

Short Interest

A high or increasing short interest implies that many investors expect the stock price to decline. You can treat that as a warning. Or you can disagree with the crowd and buy stocks with high short interest in anticipation of a short squeeze (a rally that occurs when short sellers rush to buy a stock, fearing losses they might incur if they wait too long). Prospects for a squeeze are indicated by high readings in the "Days to Cover" column (which tells how many days it would take for all short interest positions to be covered if recent trading volume levels persist). The risk: The bears may be right. So research other aspects of the company.

Month	Shares	% Outstanding	Percent of Float	Days to Cover
December 2006	2,000	0.00	0.00	0.03
November	7,000	0.01	0.01	0.10
October	6,000	0.00	0.01	0.09
September		NA	NA	NA

Stock Price Rationale

Determine if the stock price is justified by: growth-based value, comparative value, liquid assets, or dividends. The better the company, (in terms of growth or quality), the higher the valuation measures can be. And if valuation ratios are extremely low, double-check to see if the company appears excessively weak. In any case, you don't have to say yes to any valuation measure - many buy shares based on other factors (e.g., growth). But if you do that, at least understand what you're doing and consider the risks.

Viewing Things In Context

Many people erroneously work with valuation ratios calculated based on numbers that aren't truly representative of a company's underlying sustainable financial characteristics. Thus it's important to determine if today's sales and EPS are significantly depressed or elevated due to temporary factors such as business cycles. Higher ratios can be tolerated if sales and EPS are temporarily depressed. But if the company is experiencing unsustainable boom conditions, seek lower ratios. GAAP = Generally Accepted Accounting Principles.

Fiscal Year Ending			12/31/00	12/31/01	12/31/02	12/31/03	12/31/04	12/31/05E	12/31/06E
Sales/Share	NA	NA	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.01
Price/Sales	NA	NA	NA	NA	NM	108.48	NM	NM	52.41
EPS (GAAP)	NA	NA	(\$0.21)	(\$0.17)	(\$0.08)	(\$0.07)	(\$0.04)	(\$0.04)	(\$0.04)
P/E (GAAP)	NA	NA	NA	NA	NM	NM	NM	NM	NM
EPS (Normalized)	NA	NA	(\$0.21)	(\$0.17)	(\$0.08)	(\$0.07)	(\$0.04)	(\$0.04)	(\$0.04)
P/E (Normalized)	NA	NA	NA	NA	NM	NM	NM	NM	NM
Dividend Yield (%)	NA	NA	NA	NA	0.00	0.00	0.00	NA	NA

Valuation Based On Growth

The faster a company grows, the higher its stock's P/E can be. Contrary to popular belief, PEG (P/E over Growth Rate) need not always be 1.00 or less. But all else being equal, lower is better (and 3.00 is usually too high). Try to favor company PEGs that are lower than industry and market PEGs. In all cases, watch for very high growth estimates. If overly optimistic projections get cut, PEG would wind up being higher. FY = Fiscal Year.

	Price/EPS (Est.) for Current FY	Price/EPS (Est.) for Next FY	Long Term Growth Estimate	Next FY P/E over LT Growth
Samaritan Pharmaceuticals, Inc.	NM 36.84	NM 29.25	NA 21.73	NA 1.45
Biotechnology & Drugs	18.68	16.23	11.68	3.85

Comparative Valuation Ratios

Valuation below industry or S&P 500 averages can be attractive - unless the company is materially worse in terms of quality growth prospects. Year-by-year trends in comparative valuations can give clues about company merit. Be especially on guard if comparative ratios are deteriorating over time. On the other hand, relatively low valuations that are moving toward the averages might indicate that the market is tuning in to heretofore under-appreciated company merit.

FY = Fiscal Year, TTM = Trailing Twelve Months, * = Most Recent Quarter.

Samaritan Pharmaceuticals, Inc.

	Price/Earnings	Price/Sales	Price/Book	Price/Cash Flow	Price/Tang. Book	Price/Free Cash Flow
Trailing 12 Months	NA	403.05	* 19.05	NM	* 23.73	NA
FY Ending 12/31/04	NM	NM	25.48	(25.22)	28.02	(36.92)
FY Ending 12/31/03	NM	108.48	NM	(4.93)	NM	(12.07)
FY Ending 12/31/02	NM	NM	(13.12)	(2.39)	(10.35)	(4.72)
FY Ending 12/31/01	NA	NA	NA	NA	NA	NA

Bar Chart Key: 2001 TTM

Dividends

Dividend is the most classic basis for stock valuation, and high dividend yields are usually deemed preferable. Today, with many companies reinvesting profits back into the business, moderate low yields can be accepted if dividends grow rapidly. The main risk is that poor performance will cause the dividend to be cut or omitted. A very high payout ratio is one warning signal. Another is a yield that is very high relative to industry peers.

TTM = Trailing Twelve Months.

	LIV	Industry
Current Dividend Yield	NA	0.5%
5 Yr. Avg. Dividend Yield	NA	0.0%
5 Yr. Dividend Growth Rate	NA	9.0%
TTM Payout Ratio	NA	1.2%
5 Yr. Average Payout Ratio	NA	0.8%

Biotechnology & Drugs

	Price/Earnings	Price/Sales	Price/Book	Price/Cash Flow	Price/Tang. Book	Price/Free Cash Flow
Trailing 12 Months	41.95	10.72	* 7.32	35.20	* 11.76	32.64
FY Ending 2004	47.46	11.27	5.15	24.57	9.88	36.82
FY Ending 2003	43.74	11.65	5.47	24.11	9.85	28.08
FY Ending 2002	40.21	9.71	4.26	1.23	8.33	36.32
FY Ending 2001	69.23	18.98	6.85	31.19	8.29	37.80

Bar Chart Key: 2001 TTM

S&P 500

	Price/Earnings	Price/Sales	Price/Book	Price/Cash Flow	Price/Tang. Book	Price/Free Cash Flow
Trailing 12 Months	21.35	2.89	* 4.06	15.66	* 7.12	30.55
FY Ending 2004	24.10	3.23	4.01	15.67	5.23	23.74
FY Ending 2003	28.86	3.40	4.18	18.21	6.16	27.80
FY Ending 2002	27.85	3.14	4.40	16.95	5.54	25.17
FY Ending 2001	36.20	4.04	5.71	21.98	8.13	27.09

Bar Chart Key: 2001 TTM

Liquid Assets

Get a general sense of the extent to which the stock price is offset by the presence of assets that can be converted to cash immediately or in the near future. Often, these ratios will not be meaningful. Most companies are valued as ongoing businesses, rather than liquidation/buyout prospects. If you're looking at an especially troubled company, be aware that seemingly liquid-asset windfalls can be dissipated by continuing operating losses and/or shutdown costs.

Price to ...	LIV	Industry
General Working Capital (current assets minus current liabilities)	40.5	14.1
Net Working Capital (current assets minus all liabilities)	40.5	8.3
Cash (& cash equivalents)	34.0	17.2
Cash minus total debt	34.0	18.4
Cash minus all liabilities	43.0	(3.3)

Expectations And Credibility

In theory, stock prices are based on the "present value" of expected future company cash flows. Therefore, we try to obtain accurate estimates of future financial performance. But remember, these are just estimates. Since we cannot really know what will happen tomorrow, we evaluate estimates critically by seeking clues that help us distinguish between normal versus excessive degrees of uncertainty.

Estimates In Context

Below are the present consensus revenue and EPS estimates. Notice whether analysts expect recent year-to-year growth trends to persist, or are forecasting sharp improvement or deterioration. The sharper the predicted change, the greater the level of uncertainty in the forecast. (GAAP = Generally Accepted Accounting Principles)

	Revenue (\$mil)					GAAP Earnings Per Share (\$)				
	Mar 31st	Jun 30th	Sep 30th	Dec 31st	Year Total	Mar 31st	Jun 30th	Sep 30th	Dec 31st	Year Total
FY Ending 12/2002	0.0	0.0	0.0	0.0	0.0	(0.02)	(0.04)	(0.02)	(0.03)	(0.08)
FY Ending 12/2003	0.0	0.0	0.0	0.3	0.3	(0.01)	(0.01)	(0.01)	(0.04)	(0.07)
FY Ending 12/2004	0.0	0.0	0.0	0.0	0.0	(0.01)	(0.01)	(0.01)	(0.02)	(0.04)
FY Ending 12/2005	0.0	0.0	0.1	0.1 E	0.2 E	(0.01)	(0.01)	(0.01)	(0.01) E	(0.04) E
FY Ending 12/2006	NA E	NA E	NA E	NA E	1.0 E	NA E	NA E	NA E	NA E	(0.04) E

Confidence In Estimates

The range of estimates can be measured by standard deviation. The narrower the range (the lower the standard deviation compared to the "mean" estimate) and/or the greater the number of analysts, the more definitive the expectations. Note, too, the extent to which company expectations are consistent with or diverge from those for industry and/or market.

Long Term Growth Rate			Near Term Growth Rate		
Mean	# of Estimates	Standard Dev.	Mean	# of Estimates	Standard Dev.
NA	NA	NA	NA	1	NA
21.7	4	4.91	Industry	4	4.57
11.7	9	3.15	S&P 500	11	5.98

EPS Estimate Accuracy

Assess the extent to which analysts are accurate and have a handle on the earning trends by comparing Estimates to Actual figures (which may omit various charges/credits included in GAAP results). The Actual figures are the ones that are most comparable in accounting method to the Estimates. (GAAP = Generally Accepted Accounting Principles)

There is not enough data to display EPS estimate accuracy for LIV.

Reasonableness

Look at the tables below to see if analysts are expecting the company to accomplish more than it has accomplished in the past. Such things can and do happen. But the stronger the predicted future (compared to the past), the greater the burden of proof on the part of those issuing the estimates.

Annual Growth	EPS (%)	Sales (%)	Quarterly Growth	EPS (%)	Sales (%)
5 year Estimate	NA	NA	12/05 qtr. Estimate	NA	NA
2005 Estimate	NA	NA	09/05 qtr. Estimate	NA	NA
Last 5 years	NA	NA	06/05 qtr.	NA	NA
Last 3 years	NA	NA	03/05 qtr.	NA	NA
Last Year	43.5	(100.0)			
Trailing 12 Months	24.9	(46.0)			

Quarterly EPS Estimate Revisions

09/05 qtr.

There is currently not enough data available to use to display quarterly EPS estimate revisions.




12/05 qtr.

There is currently not enough data available to use to display quarterly EPS estimate revisions.



Period After Next



Analyst Recommendation Trends

Difference of opinion is normal, so don't demand unanimity. Look for ratings clusters in a part of the best-to-worst scale and at Mean Rating scores. Also important is whether analyst sentiment is improving or declining over time.

	Buy (Value 1)	Outperform (Value 2)	Hold (Value 3)	Underperform (Value 4)	Sell (Value 5)	Mean Rating
As of 1/20/06	0	0	1	0	0	3.00
As of 4 Weeks ago	0	0	1	0	0	3.00
As of 8 Weeks ago	0	0	1	0	0	3.00
As of 12 Weeks ago	0	0	1	0	0	3.00

Bar Chart Key

12 Wks ago 1/20




Mean Rating

1.00 = Best
5.00 = Worst

Annual EPS Estimate Revisions

Since estimates address an unknowable future, revision (often prompted by company guidance) is to be expected. Investors are usually happy when analysts are scrambling to chase reality upward. So increases in estimates tend to spark strong share price performance. The reverse is usually true when estimates are falling.



Footprints of Success

In many respects, business success requires subjective judgment. However, over time, good companies tend to leave good footprints, which become most visible when company data is compared to industry/sector/market benchmarks. That's how you see when companies perform well, not just because a rising business tide lifts all boats, but because the company is doing unique, good things. Look, too, at time-series comparisons, and take note of companies that are improving faster or suffering less than peers.

Growth Rates (%)

Investors are accustomed to looking at EPS growth. Check sales growth, too. EPS gains can't persist indefinitely without good sales growth. Do further investigation if sales trends are falling short. (A big short fall might reflect a divestiture. On the other hand, if sales growth looks too good, check to see if it's being boosted by an acquisition.) Also, compare sales growth to capital spending growth. Over a prolonged period, it's reasonable to expect capital spending growth to more or less keep pace with sales growth. If the latter is significantly higher, capital spending may have to accelerate in the next few years.

% Growth Rate	LIV	Industry	Sector	S&P 500	Company Rank in Industry	LIV vs. Industry	LIV vs. Sector	LIV vs. S&P 500
Sales Growth For Most Recent Quarter	NA	24.7	12.0	16.6	NA	NA	NA	NA
Sales Growth For Trailing 12 Months	(46.0)	24.3	14.1	16.8	25			
Sales Growth For Past 5 Years	NA	29.6	16.8	9.7	NA	NA	NA	NA
Capital Spending Growth for Past 5 Years	NA	34.4	16.2	(6.6)	40	NA	NA	NA
EPS Growth for Most Recent Quarter	(34.9)	13.7	3.7	18.2	NA			
EPS Growth for Trailing Twelve Months	24.9	40.0	7.5	21.8	NA			
EPS Growth for Past 5 Years	NA	10.5	14.1	14.3	NA	NA	NA	NA

Worst Best □ = Co. underperforming ■ = Co. outperforming

Company Quality

Some companies excel in obtaining high margins (watch out for very low tax rates, which may reflect special benefits that often won't persist indefinitely) while others are highly efficient. Still others are strong in both respects. These trade-offs are balanced in the Management Effectiveness returns, which combine both factors. TTM = Trailing Twelve Months.

Profitability Ratios (%)	LIV	Industry	Sector	S&P 500	Company Rank in Industry	LIV vs. Industry	LIV vs. Sector	LIV vs. S&P 500
Gross Margin for Trailing Twelve Month	NA	70.1	69.1	44.9	89	NA	NA	NA
Gross Margin for Past 5 Years	NA	69.1	68.6	44.5	99	NA	NA	NA
Operating Margin for Trailing Twelve Months	(4,541.5)	20.5	19.5	20.8	NA			
Operating Margin for Past 5 Years	NA	6.3	16.6	18.1	NA	NA	NA	NA
EBITD Margin for Trailing Twelve Month	(4,563.0)	24.7	24.3	22.2	NA			
EBITD Margin for Past 5 Years	NA	13.9	22.4	20.1	22	NA	NA	NA
Pretax Margin for Trailing Twelve Months	(4,540.0)	20.7	19.5	18.9	NA			
Pretax Margin for Past 5 Years	NA	9.2	17.2	16.6	NA	NA	NA	NA
Net Margin for Trailing Twelve Months	(4,540.0)	14.2	13.3	13.8	NA			
Net Margin for Past 5 Years	NA	3.6	11.5	11.1	NA	NA	NA	NA
Effective Tax Rate for Trailing Twelve Months	NA	31.3	31.4	30.8	NA	NA	NA	NA
Effective Tax Rate for Past 5 Years	NA	29.0	29.6	32.6	NA	NA	NA	NA
Efficiency Ratios (TTM)	LIV	Industry	Sector	S&P 500	Company Rank in Industry	LIV vs. Industry	LIV vs. Sector	LIV vs. S&P 500
Asset Turnover	0.0	0.7	0.8	1.0	27			
Receivables Turnover	NA	8.2	7.0	10.5	31	NA	NA	NA
Inventory Turnover	NA	3.1	4.2	13.5	NA	NA	NA	NA
Revenue/Employee	\$13,500	\$697,103	\$474,511	\$824,261	13			
Net Income/Employee	\$NA	\$145,294	\$81,129	\$105,293	NA	NA	NA	NA
Management Effectiveness Ratios (%)	LIV	Industry	Sector	S&P 500	Company Rank in Industry	LIV vs. Industry	LIV vs. Sector	LIV vs. S&P 500
Return on Assets for TTM	(127.0)	3.1	7.2	8.0	13			
Return on Assets for Past 5 Years	NA	(0.8)	7.7	6.3	3	NA	NA	NA
Return on Investment for TTM	(137.7)	4.2	9.6	12.0	14			
Return on Investment for Past 5 Years	NA	0.4	11.4	9.9	NA	NA	NA	NA
Return on Equity for TTM	(137.7)	8.9	14.5	20.0	20			
Return on Equity for Past 5 Years	NA	3.0	18.5	17.6	NA	NA	NA	NA

Worst Best □ = Co. underperforming ■ = Co. outperforming

Financial Strength

Quick Ratio (cash and marketable securities divided by current liabilities) and Current Ratio (all current assets divided by current liabilities) give a sense of how readily the company could cover current obligations if the sales were to stop. Higher ratios indicate greater liquidity. Different businesses have different cash inflow-outflow characteristics, so compare companies to industry averages. Similar comparisons are relevant for debt ratios (higher ratios indicate more debt and, hence, more financial risk) and interest coverage (lower numbers signify greater risk).

	LIV	Industry	Sector	S&P 500	Company Rank in Industry	LIV vs. Industry	LIV vs. Sector	LIV vs. S&P 500
Quick Ratio	5.0	3.4	2.2	1.2	66			
Current Ratio	5.0	4.1	2.8	1.7	62			
Total Debt to Equity	NA	38.9	38.1	77.6	97	NA	NA	NA
Long Term Debt to Equity	NA	35.5	31.4	53.6	75	NA	NA	NA
Interest Coverage	NA	7.8	17.0	14.0	NA	NA	NA	NA

Worst Best □ = Co. underperforming ■ = Co. outperforming